Observational studyAnnals of African medicine2026
Impact of Platinum-based versus Other Chemotherapies on Health-related Quality of Life and Hospital Anxiety and Depression Scale in Patients with Malignancies in a Tertiary Center in Western India.
Observational study in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Psychosomatics at the threshold: cancer, mood disorders, and the mental pain of death - where precision medicine meets spirituality.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer remains a significant public health concern globally, with increasing incidence in developing countries like India. While chemotherapy has improved survival rates, the quality of life and psychological well-being of cancer patients frequently deteriorate due to treatment-related toxicities, including electrolyte disturbances and psychological effects. This study aimed to examine the differential impact of platinum-based chemotherapy versus other regimens on Health-related Quality of Life (HRQoL) and Hospital Anxiety and Depression Scale (HADS) scores in cancer patients. METHODOLOGY: This cross-sectional observational study enrolled 90 cancer patients from a tertiary care center in western India between October 2023 and February 2025. Patients were categorized into three groups based on treatment: platinum-based chemotherapy ( n = 32), combination chemotherapy ( n = 28), and other treatments including immunotherapy and hormonal therapy ( n = 30). Serum electrolytes were analyzed, and patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 for HRQoL assessment and HADS questionnaire. Data were analyzed using SPSS version 21, with P < 0.05 considered statistically significant.
resultsPatients receiving platinum-based chemotherapy showed significantly worse HRQoL scores (mean: 55.4 ± 10.2) compared to combination therapy (62.8 ± 9.7) and other treatments (71.3 ± 8.5, P < 0.001). Similarly, HADS scores were highest in the platinum group (13.8 ± 3.4), indicating moderate anxiety and depression, compared to combination therapy (9.6 ± 2.7) and other treatments (6.2 ± 2.1, P < 0.001). Potassium and phosphate abnormalities were significantly more common in patients receiving platinum-based regimens ( P < 0.05) and correlated with poorer HRQoL and higher HADS scores.
conclusionPlatinum-based chemotherapy is associated with significantly worse HRQoL, higher anxiety and depression scores, and more frequent electrolyte disturbances compared to other treatment modalities. Regular monitoring of psychological well-being and electrolyte levels, along with appropriate supportive care interventions, should be integrated into routine cancer management, particularly for patients receiving platinum-based regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.